Jazz Pharmaceuticals PLC (JAZZ) Holdings Lowered by Icon Advisers Inc. Co.

Share on StockTwits

Icon Advisers Inc. Co. trimmed its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 110,994 shares of the specialty pharmaceutical company’s stock after selling 2,800 shares during the quarter. Jazz Pharmaceuticals comprises 1.6% of Icon Advisers Inc. Co.’s holdings, making the stock its 12th biggest position. Icon Advisers Inc. Co.’s holdings in Jazz Pharmaceuticals were worth $15,867,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $25,000. Prime Capital Investment Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $27,000. Carroll Financial Associates Inc. raised its holdings in shares of Jazz Pharmaceuticals by 166.7% in the 1st quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 125 shares in the last quarter. Osborn Williams & Donohoe LLC bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $33,000. Finally, Moody National Bank Trust Division bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $40,000. Institutional investors own 92.88% of the company’s stock.

Shares of NASDAQ:JAZZ opened at $129.57 on Friday. Jazz Pharmaceuticals PLC has a 12 month low of $113.52 and a 12 month high of $184.00. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.42 and a current ratio of 3.57. The stock has a market cap of $7.36 billion, a price-to-earnings ratio of 10.59, a P/E/G ratio of 1.06 and a beta of 1.16.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.66 by $0.61. The business had revenue of $476.46 million for the quarter, compared to the consensus estimate of $459.48 million. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. Jazz Pharmaceuticals’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same period last year, the company posted $2.95 EPS. Analysts expect that Jazz Pharmaceuticals PLC will post 13.19 earnings per share for the current fiscal year.

JAZZ has been the topic of a number of research reports. Cantor Fitzgerald set a $201.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, January 4th. TheStreet downgraded shares of Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Tuesday, February 19th. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, February 26th. BidaskClub downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. Finally, SunTrust Banks initiated coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, March 19th. They set a “buy” rating and a $163.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $182.71.

In related news, CFO Matthew P. Young sold 1,152 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $135.41, for a total value of $155,992.32. Following the sale, the chief financial officer now directly owns 38,700 shares in the company, valued at approximately $5,240,367. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of the stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $140.00, for a total transaction of $933,240.00. Following the completion of the sale, the executive vice president now owns 40,401 shares in the company, valued at $5,656,140. The disclosure for this sale can be found here. Insiders sold a total of 11,668 shares of company stock worth $1,606,567 over the last quarter. 3.90% of the stock is currently owned by corporate insiders.

WARNING: This article was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://weekherald.com/2019/05/03/jazz-pharmaceuticals-plc-jazz-holdings-lowered-by-icon-advisers-inc-co.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.